Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07328035

Remission in Adults With Severe Asthma in Thailand

The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand.

The main question the study aims to answer is:

What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Severe Asthma Asthma Asthma Control Level Bronchial Diseases Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Immunoproliferative Disorders Lung Diseases Lung Diseases, Obstructive Lymphatic Diseases Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This study is a cross-sectional study. Thai patients aged 18 years or older with severe asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • severe asthma
  • age 18 years or older

Exclusion criteria

  • inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test

Treatment and study plan

Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires

Other

GINA and ACT are questionnaires used to assess the level of asthma control.

Spirometry

Diagnostic Test

Spirometry is a tool used to assess pulmonary function.

Fractional exhaled nitric oxide (FeNO) test

Diagnostic Test

FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.

Blood eosinophil count (BEC)

Diagnostic Test

BEC is a tool used to assess eosinophilic inflammation and asthma remission.

Primary outcomes

  1. Prevalence rate of severe asthma remission

    Time frame: The beginning of the study

    Prevalence rate of remission in adults with severe asthma

Secondary outcomes

  1. Association of clinical characteristics with severe asthma remission

    Time frame: The beginning of the study

    The association between severe asthma remission and the following variables will be evaluated:

    • Asthma symptom control; Asthma Control Test (ACT) score (range 5-25)
    • Exacerbation history; Number of asthma exacerbations requiring systemic corticosteroids in the previous 12 months
    • Oral corticosteroid use; Daily oral corticosteroid use (yes/no) and cumulative dose (mg/year)
    • Asthma duration; Years since asthma diagnosis

  2. Association of lung function with severe asthma remission

    Time frame: The beginning of the study

    The association between severe asthma remission (binary outcome: remission vs. non-remission) and pulmonary function assessed using spirometry (FEV1 % predicted and FEV1/FVC ratio).

  3. Association of inflammatory biomarkers with severe asthma remission

    Time frame: The beginning of the study

    The association between severe asthma remission (binary outcome: remission vs. non-remission) and inflammatory biomarkers assessed using blood eosinophil count (cells/µL) and fractional exhaled nitric oxide (FeNO) (parts per billion, ppb).

Study contacts

Contact information is provided by the study sponsor or research team.

Narongkorn Saiphoklang, MD

CONTACT

[email protected]

+6629269794

Pacharaporn Tangsathapornpong, MD

CONTACT

[email protected]

+6629269701

Sponsors and collaborators

Lead sponsor

Thammasat University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 8, 2026
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.